肝脏 ›› 2026, Vol. 31 ›› Issue (8): 1160-1163.

• 自身免疫性肝病 • 上一篇    下一篇

自身免疫性肝炎患者甲状腺功能水平变化及其对治疗应答的影响

王子洪, 胡萍, 宋淘, 李翔, 高玉林   

  1. 614000 乐山 乐山市妇幼保健院内科(王子洪,胡萍,宋淘);
    710100 西安 西安航天医院药剂科(李翔);
    710065 西安 陕西省康复医院普通外科(高玉林)
  • 收稿日期:2025-09-28 出版日期:2026-08-31 发布日期:2026-09-28
  • 通讯作者: 李翔,Email:lixiang_301@126.com

Thyroid function alterations in patients with autoimmune hepatitis and their association with treatment response

Wang Zihong1, Hu Ping1, Song Tao1, Li Xiang2, Gao Yulin3   

  1. 1. Department of Internal Medicine, Leshan Maternal and Child Health Hospital, Leshan 614000, China;
    2. Department of Pharmacy, Xi′an Aerospace Hospital, Xi′an 710100;
    3. Department of General Surgery, Shaanxi Rehabilitation Hospital, Xi′an 710065, China
  • Received:2025-09-28 Online:2026-08-31 Published:2026-09-28
  • Contact: Li Xiang,Email:lixiang_301@126.com

摘要: 目的 分析自身免疫性肝炎(AIH)甲状腺功能水平变化,分析其在疾病活动性评估及治疗应答预测中的价值。方法 选取2023年8月至2025年6月乐山市妇幼保健院和西安航天医院诊治的AIH患者78例作为AIH组、健康体检者50名作为对照组,比较两组的甲状腺功能水平。治疗后,比较不同病情严重程度、治疗应答状态AIH患者的甲状腺功能水平。结果 AIH组治疗前血清FT3和FT4水平为(4.1±0.4)pmol/L、(13.8±2.2)pmol/L,均显著低于对照组[(4.8±0.6)pmol/L、(15.9±2.7)pmol/L,P<0.05],而TSH明显高于对照组[(3.7±0.8)mIU/L 比(2.8±0.6)mIU/L,P<0.05]。重度病情患者FT3及FT4分别为(3.9±0.4)pmol/L、(13.2±2.1)pmol/L,明显低于轻中度患者[(4.3±0.5)pmol/L、(14.2±2.4)pmol/L,P<0.05],而TSH明显高于轻中度患者[(4.0±0.9)mIU/L 比(3.5±0.6)mIU/L,P<0.05]。重度病情、组织学炎症≥2级、肝纤维化≥2期患者的FT3、FT4水平均低于病情轻中度、轻或无组织学炎症或肝纤维化的患者,而TSH水平显著升高(P<0.05)。治疗后,AIH患者中51例(65.4%)获得治疗应答,应答组FT3、FT4为(4.8±0.7)pmol/L、(15.8±2.7)pmol/L,显著高于未应答组[(4.2±0.4)pmol/L、(14.0±2.2)pmol/L,P<0.05],而TSH明显低于未应答组[(2.8±0.5)mIU/L 比(3.4±0.8)mIU/L,P<0.05]。结论 AIH患者甲状腺功能状态的基本特征与肝病严重程度和治疗应答之间存在潜在联系。甲状腺功能异常可能是AIH患者炎症激活、代谢失衡与免疫调节紊乱的综合反映,FT3、FT4与TSH等指标具有潜在的预后评估和治疗反应预测价值。

关键词: 自身免疫性肝炎, 甲状腺功能, 治疗应答, 肝组织炎症活动度, 肝纤维化

Abstract: Objective The present study sought to delineate alterations in thyroid function among patients with autoimmune hepatitis (AIH), with the ultimate aim of clarifying their potential role not only in the assessment of disease activity but also in the prediction of therapeutic response. Methods Seventy-eight patients diagnosed with AIH and admitted to Leshan Maternal and Child Health Hospital and Shaanxi Rehabilitation Hospital between August 2023 and June 2025, together with 50 healthy individuals who underwent routine examinations and served as controls, were included. Comparative analyses of thyroid functional indices were performed between patients and controls; subsequently, post-treatment evaluations were conducted, in which patients were stratified by disease severity and therapeutic response status. Results Before treatment, serum FT3 and FT4 levels in AIH patients were (4.1±0.4) pmol/L and (13.8±2.2) pmol/L, respectively, both significantly lower than those in the control group [(4.8±0.6) pmol/L and (15.9±2.7) pmol/L, P<0.05], while TSH was markedly higher [(3.7±0.8) mIU/L vs. (2.8±0.6) mIU/L, P<0.05]. In patients with severe disease, FT3 and FT4 levels [(3.9±0.4) pmol/L and (13.2±2.1) pmol/L] were significantly lower than those in patients with mild to moderate disease [(4.3±0.5) pmol/L and (14.2±2.4) pmol/L, P<0.05], whereas TSH was significantly higher [(4.0±0.9) mIU/L vs. (3.5±0.6) mIU/L, P<0.05]. Compared with patients with mild to moderate disease, histological inflammation grade <2, or liver fibrosis stage <2,patients with severe conditions, histological inflammation grade ≥2 or fibrosis stage ≥2 exhibited lower FT3 and FT4 levels and markedly elevated TSH levels (P<0.05). After treatment, 51 AIH patients (65.4%) achieved a therapeutic response. In the response group, FT3 and FT4 levels were (4.8±0.7) pmol/L and (15.8±2.7) pmol/L, respectively, significantly higher than those in the non-response group [(4.2±0.4) pmol/L and (14.0±2.2) pmol/L, P<0.05], while TSH was significantly lower [(2.8±0.5) mIU/L vs. (3.4±0.8) mIU/L, P<0.05]. Conclusion Characteristic alterations in thyroid function in AIH patients-alterations that appear to correlate with both the severity of hepatic involvement and the likelihood of treatment response-were identified. Such abnormalities may represent, rather than isolated endocrine derangements, a composite reflection of inflammatory activation, metabolic imbalance, and immune dysregulation. Taken together, indicators such as FT3, FT4, and TSH may thus not only carry prognostic implications but also serve as valuable predictors of therapeutic responsiveness.

Key words: Autoimmune hepatitis, Thyroid function, Treatment response, Hepatic inflammatory activity, Liver fibrosis